Infectious Diseases in Children | As of December, 86 WHO member states have added pneumococcal conjugate vaccines to the routine infant immunization schedule, according to a recent Morbidity and Mortality Report. “Important gaps in PCV intr...
This study estimates the annual population-level impact of 13-valent pneumococcal conjugate vaccine (PCV13) infant national immunization programs (NIPs) on vaccine-type and non-vaccine type invasive pneumococcal disease (IPD) incidence across all ages using national surveillance data. Methods We identifi...
Introduction of PCV10 into routine immunization began in Sindh, Pakistan in February 2013 with financing assistance from the GAVI Alliance. The vaccine was introduced with a 3+0 schedule, with doses given at 6, 10 and 14 weeks of life. No catch-up vaccination was offered. ...
Year of PCV7 introduction (vaccine schedule†) 2009 (3 + 1, with catch-up) 2009 (2 + 1, with catch-up) No PCV7 introduction 2009 (2 + 1, without catch-up) 2009 (3 + 0, without catch-up) 2000 (3 + 1, with catch-up) Year of PCV10 or PCV13 introd...
By using a simple analytic approach to compute vaccine coverage in aging cohorts from claims data, we show that PCV13 coverage rose rapidly as the PCV7 program was replaced. These estimates, validated against a CDC sentinel surveillance system in 8 states, should enable early documentation of ...
With support from Gavi, The Vaccine Alliance, LMICs, including Ghana, have introduced PCV13 as part of their childhood immunization program. In 2012, Ghana introduced PCV13 vaccination among children following the 3+0 vaccine dosing schedule. However, there are concerns about the 3+0 vaccine dosi...
Private market use of PCV uses a different schedule (3 + 1) than the NIP (2 + 1). To date, PCV10 has been chosen for the NIP and private market PCV13 use is approximately 30%. 12 Range of vaccine uptake is 49–60%. 13 Australia (non-indigenous) switched from 3 + 0 to 2 +...